Loading...
•
Dec 31, 2022
Exelixis Q4 2022 Earnings Report
Exelixis reported a decrease in GAAP net income and an increase in total revenues compared to the same quarter of the previous year, while advancing its pipeline and strategic collaborations.
Key Takeaways
Exelixis reported Q4 2022 financial results, with total revenues of $423.9 million and a GAAP diluted EPS of $(0.09). The company continued to advance its cabozantinib franchise and pipeline through clinical data readouts and new collaborations.
Total revenues for Q4 2022 were $423.9 million, compared to $451.1 million for the comparable period in 2021.
Net product revenues for Q4 2022 were $377.4 million, compared to $302.7 million for the comparable period in 2021.
GAAP net loss for Q4 2022 was $(30.2) million, or $(0.09) per share, basic and diluted, compared to GAAP net income of $95.2 million, or $0.29 per share diluted, for the comparable period in 2021.
Non-GAAP net loss for Q4 2022 was $(10.2) million, or $(0.03) per share, basic and diluted, compared to non-GAAP net income of $113.3 million, or $0.35 per share, diluted, for the comparable period in 2021.
Exelixis
Exelixis
Exelixis Revenue by Segment
Revenue by Segment
CABOMETYX Revenue
CapyFin.comCOMETRIQ Revenue
CapyFin.comLicense Revenue
CapyFin.comCollaboration Revenue
CapyFin.com Forward Guidance
Exelixis is maintaining its financial guidance for fiscal year 2023.
Positive Outlook
- Total revenues are expected to be between $1.775 billion and $1.875 billion.
- Net product revenues are expected to be between $1.575 billion and $1.675 billion.
- Cost of goods sold is expected to be 4.0% - 5.0% of net product revenues.
- Research and development expenses are expected to be between $1.000 billion and $1.050 billion.
- Selling, general and administrative expenses are expected to be between $475 million and $525 million.
Challenges Ahead
- Effective tax rate is expected to be between 20% and 22%.
- The company faces risks related to market acceptance of its products.
- The company faces risks related to increasing competition.
- The company faces risks related to its dependence on collaboration partners.
- The company faces risks related to regulatory review and approval processes.
Revenue & Expenses
Visualization of income flow from segment revenue to net income